The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

It may be early, but some blazing investments have already delivered wealth-altering gains in this young year.

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Leading hair specialists reveal the science behind hair loss, sharing vital insights about when normal shedding becomes a sign of deeper health issues.

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.